NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
25 Sep 2017

Vivet’s First Gene Therapy Product Receives European and US Orphan Drug Designation VTX 801 for Wilson’s Disease

Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product, VTX-801.
AELIX Therapeutics enrolls first patient in company’s initial therapeutic HIV vaccine clinical trial<
06 Sep 2017

AELIX Therapeutics enrolls first patient in company’s initial therapeutic HIV vaccine clinical trial

AELIX-002 phase I study will focus on evaluating the safety and immunogenicity of the HTI vaccine. 
05 Sep 2017

TiGenix obtains commercial production license for expanded manufacturing facility

TiGenix NV announces today that it has obtained a license for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid.
21 Jul 2017

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Kala Pharmaceuticals, Inc. announced that is has priced its initial public offering of 6,000,000 shares.
10 Jul 2017

Prexton announces initiation of phase II clinical testing in Parkinson’s disease

Prexton Therapeutics (Prexton), today announces the launch of phase II clinical testing of its investigational drug candidate, Foliglurax, in Parkinson’s disease (PD).
05 Jul 2017

Matthew Gantz Appointed CEO of Oxthera

OxThera AB, today announced the appointment of Matthew Gantz as their new CEO.
30 Jun 2017

Babyscripts Raises $5.7 Million to Build the Market’s Most Robust, Clinically-Validated Virtual Care Women’s Health Platform

Babyscripts, announced today that it has raised $5.7 million in new funding.
19 Jun 2017

Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

Takeda Pharma AG and TiGenix NV today announced that the Swiss Agency for Therapeutic Products has accepted for review the file on investigational compound Cx601 to treat complex perianal fistulas in patients with Crohn’s disease.
15 Jun 2017

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

TiGenix NV today announces partnerships with the largest patient advocacy groups focused on Crohn’s disease and ulcerative colitis. 
13 Jun 2017

TiGenix Launches Global Phase III Trial for Cx601

TiGenix NV today announces that it has hosted its first European investigator meeting, which formally launches the global pivotal phase III clinical trial for Cx601 for the treatment of complex perianal fistulas in patients with Crohn’s disease.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.